Replies to post #124524 on Biotech Values

[DewDiligence]

I thought the term "one-time increase" was used once during the CFO remarks and once in the q&a.

That was in reply to a question asking if the royalty rate could go down, not whether it could go up. However, as noted in my previous post in this thread, I think this distinction is without relevance.

Also, I mean tiered as in increasing royalty rate due based on increasing sales of the drug. I.e. if the tiers used to be 8-9-10-11-12%, then now would be 10-11-12-13-14% at certain thresholds.

There are no such tiers; the new royalty rate (which would pertain only if a second FDA-approved generic entered the market) is a flat low-double-digit rate.